Disrupt PAD+ Study With the Shockwave Medical M5+ Peripheral IVL System

NCT ID: NCT04585763

Last Updated: 2024-01-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 37 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-02-16
• Study Completion Date: 2022-11-21

Brief Summary

Prospective, multi-center, single-arm study of the M5+ Peripheral IVL system to treat calcified peripheral arteries.

Detailed Description

The objective of this study is to assess the safety and performance of the Shockwave M5+ Peripheral IVL System to treat calcified peripheral arteries in pre-market countries, and to assess continued safety and effectiveness in the US. A minimum of 40 lesions in up to 40 subjects at up to 10 sites in Australia, New Zealand and the US will be enrolled with the aim of treating at least 20 target lesions with the 8.0 mm IVL catheter. A maximum of three target lesions may be treated per subject. Subjects with moderate and severely calcified iliac and femoropopliteal artery disease presenting with Rutherford Category 2 to 5. Approximately 6 months of enrollment at up to 10 sites in Australia, New Zealand and the US. Study subjects will be followed through discharge, 30 days, 6 and 12 months. Duplex Ultrasound (DUS) assessments will be completed at 12 months. Total anticipated study duration is 18 months. The primary safety endpoint is Major Adverse Events (MAE) at 30 days defined as: need for emergency surgical revascularization of target limb; unplanned target limb major amputation (above the ankle); symptomatic thrombus or distal emboli that require surgical, mechanical or pharmacologic means to improve flow and extend hospitalization ; or perforations that require an intervention, including bail-out stenting. The primary performance endpoint is technical success defined as final residual stenosis ≤30% without flow-limiting dissection (≥ Grade D) of the lesion by angiographic core lab.

Conditions

Peripheral Arterial Disease; Vascular Disease, Peripheral

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Shockwave Medical M5+ Peripheral Intravascular Lithotripsy (IVL)

Group Type: EXPERIMENTAL

Shockwave Medical M5+ Peripheral Intravascular Lithotripsy (IVL)

Intervention Type: DEVICE

The Shockwave Medical M5+ Peripheral IVL System is indicated for lithotripsy-enhanced, low-pressure balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. This device is not intended for use in coronary, carotid, or cerebrovascular arteries.

Interventions

Shockwave Medical M5+ Peripheral Intravascular Lithotripsy (IVL)

The Shockwave Medical M5+ Peripheral IVL System is indicated for lithotripsy-enhanced, low-pressure balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. This device is not intended for use in coronary, carotid, or cerebrovascular arteries.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Subject is able and willing to comply with all assessments in the study.

2. Subject or subject's legal representative have been informed of the nature of the study, agrees to participate and has signed the approved consent form.

3. Age of subject is > 18.

4. Rutherford Clinical Category 2, 3, 4 or 5 of the target limb(s).

5. Estimated life expectancy >1 year.

6. Subject is intended to undergo treatment with Shockwave M5+ Peripheral IVL System for de novo lesions of the ilio-femoropopliteal arteries.

7. Single or multiple de novo target lesion(s) located from the common iliac to the femoropopliteal artery, in one or both limbs.

8. Target lesion reference vessel diameter is between 3.5mm and 8.0mm by visual estimate.

9. Target lesion is ≥70% stenosis by investigator via visual estimate.

10. Target lesion length is ≤200mm for lesions 70-99% stenosed. Target lesion can be all or part of the 200mm treated zone.

11. Chronic total occlusion, lesion length is ≤100mm of the total ≤200 mm target lesion.

12. Subject has at least one patent tibial vessel on the target leg with runoff to the foot, defined as no stenosis >50%.

13. Calcification is at least moderate defined as presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending > 50% the length of the lesion if lesion is ≥50mm in length; or extending for minimum of 20mm if lesion is <50mm in length.

Exclusion Criteria

1. Rutherford Clinical Category 0, 1, and 6.

2. Subject has active infection requiring antibiotic therapy.

3. History of endovascular or surgical procedure on the target limb within the last 30 days or planned within 30 days of the index procedure. Note: Concomitant IVL treatment to facilitate large bore access at the time of procedure is allowed.

4. Subject in whom antiplatelet or anticoagulant therapy is contraindicated.

5. Subject has known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated.

6. Subject has known allergy to urethane, nylon, or silicone.

7. Myocardial infarction within 60 days prior to enrollment.

8. History of stroke within 60 days prior to enrollment.

9. Subject has acute or chronic renal disease defined as serum creatinine of >2.5 mg/dL or >220 umol/L, unless on dialysis.

10. Subject is pregnant or nursing.

11. Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint.

12. Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.

13. The planned use of specialty balloons, re-entry or atherectomy devices in the target lesion(s).

14. In-stent restenosis within 10mm of the target zone.

15. Target lesions distal to the popliteal artery.

16. Evidence of aneurysm or thrombus in target vessel.

17. No calcium or mild calcium in the target lesion.

18. Target lesion within native or synthetic vessel grafts.

19. Subject has more than three target lesions requiring treatment.

20. Subject has significant non-target lesion (>50% stenosis or occlusion) within the target limb (e.g. iliac, common femoral or below-the-knee) not successfully treated prior to treatment of the target lesions.

21. Failure to successfully cross the guidewire across the target lesion; successful crossing defined as tip of the guidewire distal to the target lesion in the absence of flow limiting dissections or perforations.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shockwave Medical, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Midwest Cardiovascular Research Foundation

Davenport, Iowa, United States

NC Heart and Vascular Research

Raleigh, North Carolina, United States

St. John Clinic

Bartlesville, Oklahoma, United States

Prince of Wales Hospital

Randwick, New South Wales, Australia

Perth Institute of Vascular Research

Nedlands, Western Australia, Australia

Auckland City Hospital

Auckland, , New Zealand

Christchurch Hospital

Christchurch, , New Zealand

Waikato District Hospital

Hamilton, , New Zealand

Countries

United States; Australia; New Zealand

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

CP 64007

Identifier Type: -

Identifier Source: org_study_id